PTPN11 and myeloproliferative neoplasm: To investigate the timing and pathophysiology of mutant SHP2-related myeloproliferative defects, we explored the transcriptomes of HSPCs with activating mutations in SHP2, derived from sporadic JMML patients and syndromic NS/JMML-like MPN zebrafish embryos, respectively.